Von Eschenbach previously headed the National Cancer Institute and was chief academic officer at Houston’s M.D. Anderson Cancer Center. He earned a medical degree from Georgetown University School of Medicine in 1967 and worked as an instructor in urology at the University of Pennsylvania School of Medicine.
Ted DeFrank, Randy Scott, Kimberly Popovits, Joffre Baker, Steven Shak, Bradley Cole, Lester Crawford
Sample-prep kit maker Proteopure has appointed Ted DeFrank to its board of directors, the company said last week.
DeFrank is president of management consulting company Dalton Enterprises and formerly was president of Pierce Biotechnology, COO of Invitrogen, and vice president of operations at Stratagene.
Genomic Health last week said its board of directors has approved 2007 base salaries for the company’s top executives: CEO and Chairman Randy Scott will be paid $280,000; Chairman, President and COO Kimberly Popovits will be paid $340,000; CSO Joffre Baker will be paid $310,000; Chief Medical Officer Steven Shak will be paid $315,000; and CFO Bradley Cole will be paid $286,000.
The US Senate last week confirmed Andrew von Eschenbach to be the new commissioner off the Food and Drug Administration.
The Bush appointee was approved after serving as acting commissioner since September 2005 after former commissioner Lester Crawford resigned.